Financial Performance - The company reported a basic earnings per share of 1.13 yuan for 2024, an increase of 9.71% compared to 1.03 yuan in 2023 [1] - The net profit for 2024 was 11.44 billion yuan, reflecting a growth of 10.32% from 10.37 billion yuan in 2023 [1] - The total operating revenue reached 56.98 billion yuan, marking a 13.01% increase from 50.42 billion yuan in the previous year [1] - The return on equity (ROE) decreased slightly to 16.79% from 17.28% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 43,236.73 million shares, accounting for 49.01% of the circulating shares, with a decrease of 1,033.76 million shares compared to the previous period [1] - Xu Zhou Enhua Investment Co., Ltd. remains the largest shareholder with 32,009.63 million shares, representing 36.30% of the total share capital [2] - Other notable shareholders include Zhang Xu with 2,181.78 million shares and Hong Kong Central Clearing Limited with 1,404.66 million shares, both showing a decrease in holdings [2] Dividend Distribution - The company announced a dividend distribution plan of 3.6 yuan per share (including tax) [3]
恩华药业:2024年报净利润11.44亿 同比增长10.32%